How Much Does Zepbound Cost in Vermont in 2026?

Vermont Retail Pricing for Zepbound

The manufacturer list price set by Eli Lilly for Zepbound is $1,059.87 per month, regardless of dose strength. Vermont retail pharmacies charge the same price across all six single-dose pen options (2.5 mg through 15 mg), each containing four prefilled pens for a 28-day supply. This flat pricing structure means dose escalation does not increase your monthly cost.

Without insurance or a discount program, Vermont residents pay the full $1,059 at chains like CVS, Walgreens, and Kinney Drugs, as well as independent pharmacies. Price variation between Vermont pharmacies is minimal because Zepbound is a single-source branded product with no generic equivalent on the market. The wholesale acquisition cost (WAC) is uniform, and pharmacy markups on specialty injectables in Vermont rarely exceed 1-2% above WAC.

For comparison, Zepbound's list price is lower than Novo Nordisk's Wegovy (semaglutide 2.4 mg), which lists at approximately $1,349 per month. This $290 monthly difference has influenced formulary positioning at several Vermont-based employer plans, according to pharmacy benefit consultants.

Vermont Medicaid Coverage for Zepbound

Vermont Medicaid covers Zepbound with prior authorization (PA). The Department of Vermont Health Access (DVHA) requires prescribers to document a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia. The PA also requires evidence that the patient has attempted lifestyle modification (diet and exercise) for at least six months.

Vermont's Medicaid preferred drug list categorizes GLP-1 receptor agonists for weight management under a specific therapeutic class that requires step therapy. Patients may need to trial a lower-cost agent before Zepbound approval, though exceptions exist for patients with documented intolerance or contraindications to alternatives.

Processing time for PA requests in Vermont Medicaid averages 3-5 business days. Prescribers submit through the state's electronic PA portal or by fax to the pharmacy benefit manager. A 2024 analysis by the Kaiser Family Foundation found that 19 state Medicaid programs covered at least one anti-obesity medication, and Vermont is among the states that have expanded access in the 2025-2026 period.

Vermont Medicaid copays for preferred specialty drugs are capped at $3 per prescription for most beneficiaries. This makes Zepbound one of the most affordable options for Medicaid-eligible Vermonters who meet the clinical criteria and obtain PA.

Commercial Insurance Coverage in Vermont

Most large commercial insurers operating in Vermont now include Zepbound on their formularies, though coverage terms vary significantly. Blue Cross Blue Shield of Vermont, MVP Health Care, and Cigna each require prior authorization and apply step therapy or quantity limits.

Typical commercial plan coverage follows this pattern: PA requires documented BMI thresholds matching FDA labeling, plus a trial of lifestyle intervention. Some plans require failure of at least one prior anti-obesity medication. Tier placement is usually specialty (Tier 4 or 5), with coinsurance of 25-50% before any manufacturer copay assistance.

The clinical evidence supporting Zepbound's formulary inclusion is strong. In the SURMOUNT-1 trial (N=2,539), tirzepatide at the 15 mg dose produced 22.5% mean body weight reduction at 72 weeks compared to 2.4% with placebo. The 10 mg dose achieved 21.4%, and the 5 mg dose achieved 15.0%. These results represent the largest weight reductions seen in any phase 3 trial of an anti-obesity medication to date.

Vermont's state insurance regulations require that all qualified health plans sold on Vermont Health Connect (the state exchange) cover FDA-approved medications when medically necessary. A 2023 bulletin from the Vermont Department of Financial Regulation clarified that anti-obesity medications cannot be categorically excluded from coverage if they carry an FDA-approved indication for chronic weight management.

The Eli Lilly Zepbound Savings Card

Eli Lilly offers a manufacturer savings program that reduces out-of-pocket costs substantially for commercially insured patients. The Zepbound savings card covers the difference between a patient's plan copay and a floor price of $25 per monthly fill, with a maximum annual benefit of $150 per fill ($1,800 per year).

Eligibility requirements are straightforward. You must have commercial insurance (not Medicare, Medicaid, TRICARE, or any federal program), a valid prescription for Zepbound, and U.S. residency. Vermont residents can activate the card online or by calling Lilly's patient support line.

For commercially insured Vermont patients with a $200 specialty copay, the savings card reduces the out-of-pocket to $25. For those with 30% coinsurance on a $1,059 drug ($317.70 out-of-pocket), the card brings the cost down to $25 as well. The card does not apply to deductible amounts at all plans, so patients early in their benefit year may still face higher costs until the deductible is met.

Patients without any insurance coverage can access Lilly's separate cash-pay program, LillyDirect, which offers Zepbound vials (not pens) at $399 for a single-month supply or $549 for a three-month supply of the 2.5 mg and 5 mg doses. This program bypasses traditional pharmacy channels entirely.

Compounded Tirzepatide in Vermont

Compounded tirzepatide is available in Vermont through licensed 503A compounding pharmacies. These pharmacies prepare customized tirzepatide formulations under individual patient prescriptions, typically at $249 per month or less.

The legal basis for compounding tirzepatide in Vermont rests on federal law under Section 503A of the Federal Food, Drug, and Cosmetic Act. A 503A pharmacy may compound a drug that is commercially available (like tirzepatide) when the prescriber documents a clinical need for a patient-specific modification, such as a dose not commercially available or an allergy to an inactive ingredient in the branded product. Vermont's Board of Pharmacy follows FDA guidance on compounding and does not impose additional state-level restrictions beyond federal requirements.

There are real tradeoffs. Compounded tirzepatide does not undergo the same FDA approval process as Zepbound. Potency, sterility, and stability testing varies by pharmacy. The FDA has issued warnings about certain compounded semaglutide and tirzepatide products found to contain salt forms (such as tirzepatide sodium) that are not the same active ingredient as the FDA-approved product.

Vermont residents considering compounded tirzepatide should verify that the pharmacy is licensed by the Vermont Board of Pharmacy, accredited by the Pharmacy Compounding Accreditation Board (PCAB), and performs third-party potency and sterility testing. Asking for a certificate of analysis (COA) for each batch is a reasonable step.

Telehealth Access to Zepbound in Vermont

Vermont permits telehealth prescribing of Zepbound. State law allows clinicians to prescribe controlled and non-controlled medications via telemedicine when a valid provider-patient relationship is established, which can occur entirely through a video or audio visit. Zepbound is not a controlled substance, which simplifies the prescribing pathway.

Multiple national telehealth platforms serve Vermont residents for GLP-1 prescriptions, including Ro, Hims, Found, and Calibrate. HealthRX also provides telehealth evaluations for Vermont patients seeking tirzepatide. Pricing for telehealth consultations ranges from $0 (included in subscription models) to $149 for standalone evaluations.

A telehealth visit for Zepbound in Vermont typically includes a weight and metabolic health assessment, review of BMI and comorbidities, discussion of prior weight-loss attempts, and prescription issuance if clinically appropriate. The prescription is then sent electronically to the patient's pharmacy of choice, whether a retail chain, mail-order pharmacy, or compounding pharmacy.

One practical note: some telehealth platforms partner directly with compounding pharmacies and ship tirzepatide to Vermont addresses. Others write prescriptions only for brand-name Zepbound. Clarify this distinction before your consultation.

Cost Comparison: Brand vs. Compounded vs. Savings Programs

The total annual cost of Zepbound in Vermont varies dramatically depending on your coverage pathway.

Brand-name Zepbound without insurance runs $12,708 per year. With a typical commercial plan and the Lilly savings card, the annual out-of-pocket drops to approximately $300-$600. Vermont Medicaid patients pay approximately $36 per year in copays. Compounded tirzepatide at $249 per month totals $2,988 per year.

For uninsured Vermont residents, the LillyDirect vial program at $399 per month ($4,788 per year) falls between the full retail price and compounded pricing, while offering the assurance of a manufacturer-produced product. The vial format does require patients to draw up their own injections with syringes rather than using prefilled pens.

The economic analysis matters because treatment duration is indefinite. Data from the SURMOUNT-4 trial demonstrated that patients who discontinued tirzepatide after 36 weeks regained approximately 14% of body weight over the subsequent 52 weeks, compared to continued weight loss in those who remained on treatment. The Endocrine Society's 2024 clinical practice guideline on pharmacological management of obesity recommends long-term pharmacotherapy for patients who respond to treatment. This means annual cost, not per-fill cost, is the metric that should drive your decision.

How to Reduce Your Zepbound Cost in Vermont

Start with your insurance formulary. Call the number on the back of your insurance card and ask whether Zepbound is covered, what tier it sits on, and what prior authorization criteria apply. If Zepbound is not on formulary but a competing GLP-1 is, your prescriber can submit a formulary exception request citing clinical reasons (such as dual GIP/GLP-1 mechanism or superior weight-loss data from SURMOUNT-1).

If you have commercial insurance, activate the Eli Lilly savings card before filling your first prescription. The card is free, takes 2-3 minutes to set up, and pharmacies can process it as a secondary payer at the point of sale.

For uninsured patients, compare LillyDirect vial pricing ($399/month) against local 503A compounding pharmacy pricing ($249/month). The price difference is roughly $150 per month, so weigh that against the quality-assurance advantages of the manufacturer product.

Vermont residents aged 65 and older on Medicare Part D face a different calculation. Medicare does not cover anti-obesity medications under the current statutory exclusion, though the Treat and Reduce Obesity Act has been reintroduced in Congress. Until that changes, Medicare beneficiaries must pay entirely out of pocket or use compounded alternatives.

Check whether your employer offers a health reimbursement arrangement (HRA) or flexible spending account (FSA) that covers anti-obesity medications. The IRS classifies Zepbound as a deductible medical expense when prescribed for a diagnosed medical condition, meaning HSA and FSA funds can be applied to your copay or the full cash price.

Clinical Considerations Before Starting Zepbound

Tirzepatide is a dual GIP and GLP-1 receptor agonist administered as a once-weekly subcutaneous injection. The starting dose is 2.5 mg weekly for four weeks, then escalating to 5 mg. Subsequent dose increases occur in 2.5 mg increments at minimum four-week intervals, up to a maximum of 15 mg weekly.

The most common side effects in SURMOUNT-1 were gastrointestinal: nausea (24-33% depending on dose), diarrhea (18-23%), constipation (11-17%), and vomiting (6-13%). Most GI events were mild to moderate and occurred primarily during dose escalation. The FDA prescribing information includes a boxed warning regarding thyroid C-cell tumors observed in rodent studies, though no causal link has been established in humans.

Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2. It should not be used in combination with other GLP-1 receptor agonists or with insulin for the purpose of weight management.

Vermont clinicians prescribing Zepbound should monitor patients for pancreatitis symptoms, gallbladder events (cholelithiasis risk increases with rapid weight loss), and changes in renal function. A baseline lipid panel, HbA1c, and hepatic function panel are standard before initiating therapy.

Patients on insulin or sulfonylureas for type 2 diabetes require dose reduction of those agents when starting tirzepatide, as the risk of hypoglycemia increases with combination use. The recommended approach is a 50% reduction in sulfonylurea dose at tirzepatide initiation, with further adjustment based on glucose monitoring.